MEETINGS - Molecular & Genetic Diagnostics: Profiting from Novel Diagnostics that Assess Disease Risk, Disease Presence & Treatment Response (UK) October 1999:
This article was originally published in Clinica
IBC Conferences will hold a meeting on Molecular & Genetic Diagnostics: Profiting from Novel Diagnostics that Assess Disease Risk, Disease Presence & Treatment Response in London on October 4-5. Dr Uwe Bicker, executive chairman and director of Dade Behring and president of the European Diagnostic Manufacturers Association (EDMA), will present the keynote speech on growth & shift in the diagnostics industry. Representatives from companies including Roche Molecular Systems, Shield Diagnostics and Nycomed Amersham Imaging will discuss some of the latest developments in this field. For more details contact IBC in the UK. Tel: +44 20 7453 5496. Fax: +44 20 7636 6858. Website: www.ibc-uk.com/it1135
You may also be interested in...
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.
In second letter this year targeting email communications, OPDP says that putting the methotrexate oral solution’s risk information below the signature block does not offer ‘prominence and readability’ comparable to the information on the drug’s effectiveness for the treatment of acute lymphoblastic leukemia that was in the body of the email.